论文部分内容阅读
目的 :从甲状腺自身免疫方面探讨1 3 1 I治疗甲亢的效果及甲低发生的因素。方法 :选择1 3 1 I治疗的88例Graves’病甲亢患者随访 3年 ,分为第 1组 (TGA、TMA、TRAb均阳性 )和第二组 (TGA、TMA阴性 ,TRAb阳性 )。采用x2 分析自身抗体水平与甲低发生的关系。结果 :1组甲低发生率为 31 4 % ,2组为 3 8% ,1组明显高于 2组 ,差异有显著性。结论 :TGA、TMA和TRAb水平与确定1 3 1 I剂量及甲低的发生关系密切。认为TGA、TMA水平高的患者应酌情减少1 3 1 I用量
Objective: From the perspective of thyroid autoimmunity, investigate the effect of 131I on the treatment of hyperthyroidism and the causes of hypothyroidism. Methods: A total of 88 Graves’ patients with hyperthyroidism were enrolled in this study. They were followed up for 3 years and divided into group 1 (positive for TGA, TMA and TRAb) and group 2 (negative for TGA, TMA negative and positive for TRAb). X2 analysis of the relationship between autoantibodies and hypothyroidism. Results: The incidence of hypothyroidism in group 1 was 31.4%, in group 2 was 38%, in group 1 was significantly higher than that in group 2, the difference was significant. Conclusion: The levels of TGA, TMA and TRAb are closely related to the determination of 131 I dose and hypothyroidism. Patients who consider TGA and TMA high should reduce their dosage by as much as 131 I